Biogen (BIIB) Goodwill & Intangibles (2009 - 2026)
Biogen (BIIB) posted quarterly Goodwill & Intangibles of $15.5 billion for Q1 2026, down 3.23% year-over-year from $16.1 billion in Q1 2025, and down 0.81% on a QoQ basis from $15.7 billion in Q4 2025.
Biogen (BIIB) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Biogen (BIIB) has reported Goodwill & Intangibles for 18 consecutive years, with $15.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Goodwill & Intangibles fell 3.23% year-over-year to $15.5 billion; the TTM figure through Mar 2026 stood at $15.5 billion (down 3.23% YoY), while the FY2025 annual figure was $15.7 billion, down 3.1% from the prior year.
- Goodwill & Intangibles came in at $15.5 billion for Q1 2026 at Biogen, down from $15.7 billion in the prior quarter.
- The five-year high for Goodwill & Intangibles was $16.3 billion in Q3 2024, with the low at $6.9 billion in Q3 2023.
- Average Goodwill & Intangibles over 5 years is $12.2 billion, with a median of $14.5 billion recorded in 2024.
- Across the five-year window, Goodwill & Intangibles retreated 10.87% in 2023 and surged 135.85% in 2024, its largest moves.
- Year by year, Goodwill & Intangibles stood at $7.6 billion in 2022, then soared by 91.89% to $14.6 billion in 2023, then rose by 10.89% to $16.2 billion in 2024, then declined by 3.1% to $15.7 billion in 2025, then decreased by 0.81% to $15.5 billion in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $15.5 billion, $15.7 billion, and $15.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.54 Bn |
| Dec 31, 2025 | 15.67 Bn |
| Sep 30, 2025 | 15.82 Bn |
| Jun 30, 2025 | 15.96 Bn |
| Mar 31, 2025 | 16.06 Bn |
| Dec 31, 2024 | 16.17 Bn |
| Sep 30, 2024 | 16.29 Bn |
| Jun 30, 2024 | 14.46 Bn |
| Mar 31, 2024 | 14.51 Bn |
| Dec 31, 2023 | 14.58 Bn |
| Sep 30, 2023 | 6.91 Bn |
| Jun 30, 2023 | 7.53 Bn |
| Mar 31, 2023 | 7.57 Bn |
| Dec 31, 2022 | 7.60 Bn |
| Sep 30, 2022 | 7.75 Bn |
| Jun 30, 2022 | 7.82 Bn |
| Mar 31, 2022 | 7.91 Bn |
| Dec 31, 2021 | 7.98 Bn |
| Sep 30, 2021 | 8.05 Bn |
| Jun 30, 2021 | 8.15 Bn |